Abstract Purpose of Review Treatment of elderly patients with acute myeloid leukemia is a
known challenge for hematologists due to patient diversity, heterogeneous disease biology …

Research has resulted in regulatory approval of nine agents for acute myeloid leukaemia
indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor …

Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS)
compared with 7+ 3 chemotherapy in older patients with secondary acute myeloid leukemia …

Accurate classification and risk stratification are critical for clinical decision making in
patients with acute myeloid leukemia (AML). In the newly proposed World Health …

We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML)
versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) …

Background CPX-351, an encapsulated form of cytarabine and daunorubicin, has shown
greater efficacy than the classic 3+ 7 treatment administration in secondary acute myeloid …

Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …

Mutations in NPM1, also known as nucleophosmin-1, B23, NO38, or numatrin, are seen in
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …

Background Approximately 20,000 Americans are diagnosed with AML each year at a
median age of diagnosis of 69, and the 5-year survival is approximately 31.7%(https://seer …

Background Many older patients with acute myeloid leukaemia die or cannot undergo
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …